Mild increases in pancreatic enzymes such as lipase and amylase can occur without causing clinical pancreatitis
Medicare Part D coverage expansion: The proposed CMS rule allowing Medicare Part D plans to cover anti-obesity medications would make 31 million Medicare beneficiaries with obesity eligible for semaglutide and tirzepatide, representing a USD 55.8 billion annual drug spend potential at 15% initial penetration
(Hims & Hers, NYSE: HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first approach to weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success
This weekly dosing schedule is designed to provide consistent appetite suppression and help support weight loss over time
Thus, our department has been a pioneer in utilizing these drugs since the early evidence demonstrated their efficacy